Arcadia Wealth Management Inc. Makes New $527,000 Investment in Pfizer Inc. (NYSE:PFE)

Arcadia Wealth Management Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 19,850 shares of the biopharmaceutical company's stock, valued at approximately $527,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.43 on Wednesday, hitting $23.18. The company had a trading volume of 36,659,825 shares, compared to its average volume of 41,097,811. The company has a market cap of $131.79 billion, a PE ratio of 16.44, a PEG ratio of 0.64 and a beta of 0.58. The business has a 50 day moving average of $23.28 and a 200 day moving average of $25.12. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the company earned $0.82 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.42%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.